NVX-207 decreases cell death via apoptosis. NVX-207 has high cytotoxicity (IC50: ranging from 7.6-8.5 μM), in the three analyzed malignant glioma cell lines. NVX-207 leads to PARP cleavage and to a decrease in Survivin expression levels under normoxic and hypoxic conditions. NVX-207 displays anti-tumor activity (mean IC50 = 3.5 μM) against various human and canine cell lines. NVX-207-induced apoptosis is associated with activation of the intrinsic apoptotic pathway via cleavage of caspases -9, -3, -7, and of poly (ADP-ribose) polymerase (PARP). NVX-207 (20 μM) induces a significantly high rate of necrosis of glioma cell lines[1][2].

The intravenous application of NVX-207 is well tolerated in mice[1].